



Date: 16 January 2017

Sydney, Australia

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office:

Suite 1 Level 6
50 Queen St
Melbourne VIC 3000
Australia

Operational Office:

Suite 4 Level 3, Bdg 2
20 Bridge St
Pymble NSW 2073
Australia

Board of Directors

Mr Peter Marks

Chairman
Non-Executive
Director

Dr Graham Kelly

Chief Executive Officer
Managing Director

Dr Ian Dixon

Non-Executive
Director

APPOINTMENT OF NEW COMPANY SECRETARY

Noxopharm Ltd today confirms the appointment of David Franks as Company Secretary.

David replaces Melbourne-based Phillip Hains and his team who oversaw the Company's IPO and ASX-listing process. With the Company's administrative activities now being based in Sydney, the need for a Sydney-based company secretarial and financial officer service became necessary.

David is a Chartered Accountant, Fellow of the Financial Services Institute of Australasia, Justice of Peace and Registered Tax Agent, with over 20 years' experience as a Director and Company Secretary of numerous publicly listed entities. He holds a Bachelor of Economics (Finance and Accounting) from Macquarie University.

David is an experienced Company Secretary and Director of listed and unlisted public companies and principal of Franks and Associates Pty Limited (Chartered Accountants). David is currently Company Secretary for the following public companies: Armidale Investment Corporation Limited, Elk Petroleum Limited, JCurve Solutions Limited, Pulse Health Limited, Tomorrow Entertainment Limited, White Energy Company Limited and White Energy Technology Limited.

About Noxopharm

Noxopharm is an Australian drug development company with offices in Melbourne and Sydney. The Company has a primary focus on the development of drugs to address the problem of drug-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development in an R&D program.

About NOX66

NOX66 is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil, developed specifically to protect idronoxil from being inactivated in the human body by Phase 2 metabolism. Its purpose is to ensure that most idronoxil administered remains in an active form. Idronoxil works by cancelling pro-survival mechanisms in cancer cells regulated by sphingosine-1-phosphate that allow the cells to resist the killing effects of chemotherapies and radiotherapy.

INVESTOR AND MEDIA ENQUIRIES: Prue Kelly

E: info@noxopharm.com

T: + 61 2 9144 2223

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.